As economies all around the world are suffering from the impact of Covid-19, businesses are experiencing losses, workers are without jobs, and many face the challenge of a complete upheaval of lifestyle. However, pharmaceutical companies taking centre stage in the Covid-19 fight and a new innovation in the infectious disease landscape as the race for treatment approval for a Covid-19 therapy takes off.
Pharmaceutical companies are on the line and their impact on the fight against the virus will not be easily forgotten. The concept of large profits coming from newly developed drugs will increased consider in a time of global pandemic as a result of public and competitive pressures.
Title : Nanomaterial-mediated systemically-administered m-rna-based Gene therapy directed exclusively to cancer, resulting in eradication of implanted orthotopic tumors with no side effects
A C Matin, Stanford University, United States
Title : Mucoadhesive electrospun fibers in oral drug delivery
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Qualitative and quantitative measures of drugs’ placenta permeability - a chromatographic and computational approach
Anna Weronika Sobańska, Medical University of Lodz, Poland
Title : The signification of the blood-brain barrier to the transfer of essential and toxic mineral elements
Bartolome Ribas Ozonas, Royal National Academy of Pharmacy, Spain
Title : New excipient to formulate poorly soluble APIs
Rajendran Arunagiri, Eastman, United States
Title : Multi-detection of pharmaceutical contamination in environment
Andreia Freitas, INIAV and REQUIMTE, Portugal
Title : HDAC inhibitors with non-hydroxamate warhead
Franz Josef Meyer Almes, University of Applied Sciences, Germany
Title : The role of non-antibiotic drugs on the development of antibiotic resistance
Mujde Eryilmaz, Ankara University, Turkey
Title : Digital health: Education in clinical pharmacy and implementation in practice
Aysu selcuk, Ankara University, Turkey
Title : Pharmacovigilance – Important, current trends, challenges and opportunities
Gurpreet Singh, Freyr Lifesciences Limited, United Kingdom